Insider Selling: Incyte Corporation (INCY) Insider Sells 3,915 Shares of Stock

Incyte Corporation (NASDAQ:INCY) insider David W. Gryska sold 3,915 shares of the business’s stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $105.63, for a total transaction of $413,541.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Shares of Incyte Corporation (NASDAQ INCY) opened at $105.12 on Wednesday. Incyte Corporation has a one year low of $98.49 and a one year high of $153.15. The company has a current ratio of 4.82, a quick ratio of 4.81 and a debt-to-equity ratio of 0.01.

Incyte Corporation (NASDAQ:INCY) last posted its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.11. Incyte Corporation had a negative net margin of 10.90% and a negative return on equity of 12.91%. The firm had revenue of $381.50 million during the quarter, compared to analyst estimates of $360.34 million. During the same quarter in the prior year, the business posted $0.19 EPS. The business’s revenue was up 41.6% compared to the same quarter last year. analysts expect that Incyte Corporation will post -1.3 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Insider Selling: Incyte Corporation (INCY) Insider Sells 3,915 Shares of Stock” was first published by Week Herald and is the sole property of of Week Herald. If you are reading this report on another domain, it was copied illegally and reposted in violation of US and international copyright laws. The correct version of this report can be accessed at https://weekherald.com/2017/11/15/incyte-corporation-incy-insider-sells-413541-45-in-stock.html.

A number of brokerages have recently issued reports on INCY. Oppenheimer Holdings, Inc. set a $135.00 price target on shares of Incyte Corporation and gave the stock a “hold” rating in a research report on Tuesday, October 31st. BMO Capital Markets boosted their target price on shares of Incyte Corporation from $162.00 to $166.00 and gave the company an “outperform” rating in a research report on Tuesday, October 31st. J P Morgan Chase & Co reiterated a “buy” rating on shares of Incyte Corporation in a research report on Tuesday, October 31st. Goldman Sachs Group, Inc. (The) initiated coverage on shares of Incyte Corporation in a research report on Friday, October 6th. They set a “buy” rating and a $160.00 target price on the stock. Finally, Jefferies Group LLC reiterated a “buy” rating on shares of Incyte Corporation in a research report on Friday, October 6th. Seven equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $144.98.

A number of institutional investors and hedge funds have recently bought and sold shares of INCY. Thrivent Financial For Lutherans bought a new position in Incyte Corporation during the first quarter valued at about $865,000. Dimensional Fund Advisors LP grew its position in Incyte Corporation by 18.1% during the first quarter. Dimensional Fund Advisors LP now owns 464,549 shares of the biopharmaceutical company’s stock valued at $62,105,000 after buying an additional 71,111 shares during the period. Highbridge Capital Management LLC grew its position in Incyte Corporation by 22.5% during the first quarter. Highbridge Capital Management LLC now owns 3,570 shares of the biopharmaceutical company’s stock valued at $478,000 after buying an additional 655 shares during the period. AQR Capital Management LLC grew its position in Incyte Corporation by 1,626.0% during the first quarter. AQR Capital Management LLC now owns 94,928 shares of the biopharmaceutical company’s stock valued at $12,689,000 after buying an additional 89,428 shares during the period. Finally, First American Trust FSB bought a new position in Incyte Corporation during the second quarter valued at about $4,768,000. Institutional investors own 89.53% of the company’s stock.

Incyte Corporation Company Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Insider Buying and Selling by Quarter for Incyte Corporation (NASDAQ:INCY)

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply